Editas Medicine, Inc. (LON:0IFK)

Market Cap	157.54M
Revenue (ttm)	27.74M
Net Income (ttm)	-194.45M
Shares Out	n/a
EPS (ttm)	-2.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,458
Average Volume	55,396
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.920 - 5.971
Beta	n/a
RSI	63.07
Earnings Date	Aug 1, 2025

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporate...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2013
• Employees: 246
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IFK

Financial Performance

In 2024, Editas Medicine's revenue was $32.31 million, a decrease of -58.64% compared to the previous year's $78.12 million. Losses were -$237.09 million, 54.7% more than in 2023.

Financial numbers in USD